Last updated: November 5, 2024
Sponsor: Poznan University of Medical Sciences
Overall Status: Active - Recruiting
Phase
N/A
Condition
Congestive Heart Failure
Chest Pain
Heart Failure
Treatment
N/AClinical Study ID
NCT06679179
199/23
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
diagnosed heart failure NYHA class II and III
consent to participate in the study
patients should already be receiving treatment with an ACE inhibitor orsacubitril/valsartan or sartans, a beta-blocker, and an MRA, and should start onSGLT2i as part of therapy enhancement
Exclusion
Exclusion Criteria:
Study Design
Total Participants: 50
Study Start date:
March 10, 2023
Estimated Completion Date:
February 28, 2026
Study Description
Connect with a study center
University Clinical Hospital in Poznań, 49 Przybyszewskiego Street, 60-355 Poznań
Poznan, Wielkopolska 60-355
PolandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.